GlassScriptPhysician profile
Andrew Charles Harrison
NPI 1649769878
$2,868.54
in general payments reported to CMS, 2019-2025
23 companies · $551 in 2025
The $551 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $715 · 2022: $548 · 2023: $564 · 2024: $491 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,606.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $919.62 | 2021-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $521.67 | 2022-2025 | |
| Amgen INC. | $390.34 | 2021-2025 | Repatha, Repatha |
| Pfizer INC. | $133.76 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.76 | 2023-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $115.55 | 2023 | Brilinta |
| E.R. Squibb & Sons, L.L.C. | $115.53 | 2022-2024 | Eliquis |
| Genzyme Corporation | $113.67 | 2021 | |
| Merck Sharp & Dohme LLC | $85.93 | 2021-2024 | Verquvo |
| Novo Nordisk INC | $53.05 | 2025 | Wegovy, Ozempic |
| Scpharmaceuticals INC. | $33.23 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.05 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $31.50 | 2023-2024 | Opsumit, Uptravi |
| Kiniksa Pharmaceuticals, LTD. | $31.23 | 2023 | Arcalyst |
| Janssen Biotech, INC. | $27.87 | 2024 | Stelara |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $18.99 | 2023 | |
| Lilly USA, LLC | $18.93 | 2024 | Emgality |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.24 | 2022 | |
| Tactile Systems Technology INC | $18.07 | 2024 | Entre Plus, Flexitouch Plus |
| Regeneron Healthcare Solutions, INC. | $17.47 | 2023 | Evkeeza |
| Philips North America LLC | $16.51 | 2025 | Mcot |
| Glaxosmithkline, LLC. | $14.80 | 2025 | Shingrix, Arexvy |
| W. L. Gore & Associates, INC. | $14.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.